Synlogic Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
SYBX
- Investments
-
1
- Share Price
-
$1.50
- (As of Friday Closing)
Synlogic General Information
Description
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Contact Information
Website
www.synlogictx.comCorporate Office
- 301 Binney Street
- Suite 402
- Cambridge, MA 02142
- United States
Corporate Office
- 301 Binney Street
- Suite 402
- Cambridge, MA 02142
- United States
Synlogic Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.50 | $1.52 | $1.22 - $5.12 | $17.5M | 11.7M | 10K | -$4.64 |
Synlogic Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (286) | 20,163 | (17,711) | 39,971 |
| Revenue | 3,170 | 3,371 | 1,180 | 1,754 |
| EBITDA | (57,126) | (57,778) | (64,892) | (58,326) |
| Net Income | (56,164) | (57,282) | (66,147) | (60,561) |
| Total Assets | 21,635 | 75,550 | 110,865 | 174,736 |
| Total Debt | 0 | 17,275 | 20,298 | 20,593 |
Synlogic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Synlogic Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Synlogic Comparisons
Industry
Financing
Details
Synlogic Competitors (112)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dermata | Formerly VC-backed | San Diego, CA | ||||
| EyePoint Pharmaceuticals | Corporation | Watertown, MA | ||||
| Genfit | Formerly VC-backed | Loos, France | ||||
| Omeros | Formerly VC-backed | Seattle, WA | ||||
| Cyclerion Therapeutics | Corporation | Cambridge, MA |
Synlogic Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Synlogic Patents
Synlogic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4398923-A1 | Engineered phenylalanine ammonia lyase enzymes | Pending | 08-Sep-2021 | ||
| AU-2022340814-A1 | Recombinant cells for treating diseases associated with uric acid and methods of use thereof | Pending | 01-Sep-2021 | ||
| US-20230063093-A1 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Active | 11-Aug-2021 | ||
| US-11859189-B2 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Active | 11-Aug-2021 | ||
| AU-2022327173-A1 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Pending | 11-Aug-2021 | C12N9/88 |
Synlogic Executive Team (26)
| Name | Title | Board Seat |
|---|---|---|
| Antoine Awad | Chief Executive Officer | |
| Caroline Kurtz | Chief Development Officer | |
| Mary Dooley | Executive | |
| Ajay Munshi | Vice President & Head of Corporate Development | |
| James Collins Ph.D | Co-Founder |
Synlogic Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edward Mathers | New Enterprise Associates | Board Member | |
| Michael Heffernan | Self | Board Member | |
| Nick Leschly | Self | Board Member | |
| Peter Barrett Ph.D | Atlas Venture | Chairman & Board Member | |
| Richard Shea | Self | Board Member |
Synlogic Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Synlogic Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Mirna Therapeutics | 28-Aug-2017 | Biotechnology |
Synlogic ESG
Risk Overview
Risk Rating
Updated February, 02, 2020
30.2 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,035
Rank
Percentile
Pharmaceuticals
Industry
of 806
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Synlogic FAQs
-
When was Synlogic founded?
Synlogic was founded in 2007.
-
Who is the founder of Synlogic?
Alison Silva, Dean Falb Ph.D, Ankit Mahadevia MD, James Collins Ph.D, and Timothy Lu MD are the founders of Synlogic.
-
Who is the CEO of Synlogic?
Antoine Awad is the CEO of Synlogic.
-
Where is Synlogic headquartered?
Synlogic is headquartered in Cambridge, MA.
-
What is the size of Synlogic?
Synlogic has 6 total employees.
-
What industry is Synlogic in?
Synlogic’s primary industry is Drug Discovery.
-
Is Synlogic a private or public company?
Synlogic is a Public company.
-
What is Synlogic’s stock symbol?
The ticker symbol for Synlogic is SYBX.
-
What is the current stock price of Synlogic?
As of 04-Oct-2024 the stock price of Synlogic is $1.50.
-
What is the current market cap of Synlogic?
The current market capitalization of Synlogic is $17.5M.
-
What is Synlogic’s current revenue?
The trailing twelve month revenue for Synlogic is $3.17M.
-
Who are Synlogic’s competitors?
Dermata, EyePoint Pharmaceuticals, Genfit, Omeros, and Cyclerion Therapeutics are some of the 112 competitors of Synlogic.
-
What is Synlogic’s annual earnings per share (EPS)?
Synlogic’s EPS for 12 months was -$4.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
